老虎證券

FDA expands approval of BioCryst's rare disease drug for use in young children

Reuters
2025/12/12
FDA expands approval of BioCryst's rare disease drug for use in young children

Dec 12 (Reuters) - The U.S. Food and Drug Administration has expanded the use of BioCryst Pharmaceuticals' BCRX.O drug to include an oral pellet formulation for preventing hereditary angioedema attacks in children aged 2 to under 12 years, the company said on Friday.

(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber)

((siddhi.mahatole@thomsonreuters.com;))

應版權方要求，你需要登入查看該內容

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10